Abstract
PURPOSE: Methylnaltrexone (Relistor) is a peripherally acting µ-opioid receptor antagonist indicated for opioid-induced constipation (OIC). In laxative-refractory patients with OIC and advanced illness, such as cancer, multiple doses of methylnaltrexone may be beneficial. We assessed rescue-free laxation (RFL) responses for each successive dose of methylnaltrexone or placebo (≤7 doses) in patients with and without cancer. METHODS: Two multicenter, randomized, double-blind, placebo-controlled, institutional review board–approved studies in adults with OIC and advanced illness, stratified by cancer and noncancer, were pooled (study 302, NCT00402038; study 4000, NCT00672477).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
